Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets
- 1 December 2004
- journal article
- Published by Bioscientifica in Journal of Endocrinology
- Vol. 183 (3) , R1-R9
- https://doi.org/10.1677/joe.1.05989
Abstract
MEPE (Matrix Extracellular PhosphoglycoprotEin) expression is markedly elevated in X-linked-hypophosphatemic-rickets (HYP) and tumor-induced osteomalacia (TIO). In normal individuals, circulating serum-levels of MEPE are tightly correlated with serum-phosphorus, parathyroid hormone (PTH) and bone mineral density (BMD). Also, MEPE derived, C-terminal ASARM-peptides are candidate minhibins and/or phosphatonins. Our aims were to determine: 1. whether MEPE-ASARM-peptide(s) are abnormally elevated in HYP/hyp serum, and, 2. whether the ASARM-peptide(s) accumulate in hyp mice kidney renal-tubules. Using a specific competitive ELISA we measured a five fold increase (P=0.007) of serum ASARM-peptide(s) in human HYP patients (normal subjects 3.25 μM n=9; s.e.m.=0.51 and HYP-patients 15.74 μM, n=9; s.e.m.=3.32). A 6.23 fold increase (P=0.008) was measured in hyp male mice compared with their normal male siblings (normal-siblings, 3.73 μM, s.e.m.=0.57, n=3; and hyp-mice 23.4 μM, n=3, s.e.m.=4.01). Renal immuno-histological screening also revealed a dramatic increase of ASARM-peptides in regions anatomically consistent with the proximal convoluted tubules. This study demonstrates for the first time that markedly elevated serum levels of protease-resistant ASARM-peptide(s) occur in HYP/hyp and they accumulate in murine hyp kidneys. These peptides are thus likely responsible for the phosphaturia and defective mineralization in HYP/hyp and TIO.Keywords
This publication has 42 references indexed in Scilit:
- Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE–ASARM motif: a model for impaired mineralization in X-linked rickets (HYP)Bone, 2004
- Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human boneJournal of Bone and Mineral Metabolism, 2004
- MEPE has the properties of an osteoblastic phosphatonin and minhibinBone, 2004
- Regulation of Fibroblastic Growth Factor 23 Expression but Not Degradation by PHEXJournal of Biological Chemistry, 2003
- MEPE, the Gene Encoding a Tumor-Secreted Protein in Oncogenic Hypophosphatemic Osteomalacia, Is Expressed in BoneGenomics, 2001
- Extracts from tumors causing oncogenic osteomalacia inhibit phosphate uptake in opossum kidney cellsJournal of Endocrinology, 2001
- Flexible Structures of SIBLING Proteins, Bone Sialoprotein, and OsteopontinBiochemical and Biophysical Research Communications, 2001
- Coordinated Maturational Regulation of PHEX and Renal Phosphate Transport Inhibitory Activity: Evidence for the Pathophysiological Role of PHEX in X-Linked HypophosphatemiaJournal of Bone and Mineral Research, 1999
- Pex Gene Deletions in Gy and Hyp Mice Provide Mouse Models for X-Linked HypophosphatemiaHuman Molecular Genetics, 1997
- Use of phosphonocarboxylic acids as inhibitors of sodium-phosphate cotransportGeneral Pharmacology: The Vascular System, 1996